Xenon Pharmaceuticals (XENE) Stock Overview
A neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
XENE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Xenon Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$55.23 |
| 52 Week High | US$63.95 |
| 52 Week Low | US$26.74 |
| Beta | 0.94 |
| 1 Month Change | 29.16% |
| 3 Month Change | 25.35% |
| 1 Year Change | 56.37% |
| 3 Year Change | 64.42% |
| 5 Year Change | 192.07% |
| Change since IPO | 426.00% |
Recent News & Updates
Recent updates
Late Stage Neuroscience Pipeline Will Transform Ion Channel Franchise Over The Coming Years
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel targeted medicines for epilepsy, neuropsychiatric conditions and pain. What are the underlying business or industry changes driving this perspective?Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
Oct 01
Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release
Aug 12We're Not Very Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Rate
May 07Xenon- A Later Stage Story
Apr 18Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Jan 16Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
Aug 09Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Feb 08Xenon started at outperform at Raymond James on experimental epilepsy drug
Oct 19Putting Xenon Pharmaceuticals Back In The Spotlight
Sep 06Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Aug 29Sizing Up Xenon Pharmaceuticals
Dec 13Shareholder Returns
| XENE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 31.7% | -1.0% | -1.6% |
| 1Y | 56.4% | 23.6% | 17.7% |
Return vs Industry: XENE exceeded the US Biotechs industry which returned 25.1% over the past year.
Return vs Market: XENE exceeded the US Market which returned 20.4% over the past year.
Price Volatility
| XENE volatility | |
|---|---|
| XENE Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: XENE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XENE's weekly volatility has increased from 9% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 364 | Ian Mortimer | www.xenon-pharma.com |
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain.
Xenon Pharmaceuticals Inc. Fundamentals Summary
| XENE fundamental statistics | |
|---|---|
| Market cap | US$5.43b |
| Earnings (TTM) | -US$345.91m |
| Revenue (TTM) | US$7.50m |
Is XENE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XENE income statement (TTM) | |
|---|---|
| Revenue | US$7.50m |
| Cost of Revenue | US$300.94m |
| Gross Profit | -US$293.44m |
| Other Expenses | US$52.47m |
| Earnings | -US$345.91m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.69 |
| Gross Margin | -3,912.51% |
| Net Profit Margin | -4,612.13% |
| Debt/Equity Ratio | 0% |
How did XENE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/13 18:47 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xenon Pharmaceuticals Inc. is covered by 27 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| John Newman | Canaccord Genuity |